-

Mauna Kea Technologies to Host a Webinar on July 21, 2026 To Discuss Its First-Half Business Activity

PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announces that it will host a webinar for its shareholders and the financial community on Tuesday, July 21, 2026.

Sacha Loiseau, Chairman and Chief Executive Officer, and Côme de La Tour du Pin, Chief Financial Officer of the Company, will provide live commentary on the key highlights of the first half of 2026. The presentation will be followed by a Q&A session.

Advance registration is required to participate in the event.

Webinar for shareholders and investors – Tuesday, July 21 2026

5:50 pm. (CEST) – French Session: Click here to register

A replay will be available for registered participants.

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.

Contacts

Mauna Kea Technologies
investors@maunakeatech.com

NewCap - Investor Relations
Thomas Grojean
+33 (0)1 44 71 94 94
maunakea@newcap.eu

Mauna Kea Technologies

BOURSE:ALMKT

Release Versions

Contacts

Mauna Kea Technologies
investors@maunakeatech.com

NewCap - Investor Relations
Thomas Grojean
+33 (0)1 44 71 94 94
maunakea@newcap.eu

More News From Mauna Kea Technologies

Mauna Kea Technologies Reports Nine-Month 2026 Sales of €4.4 Million, Up 24% at Constant Exchange Rates

PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today reports its sales for the third quarter and the first nine months of 2026. “Over nine months our sales grew 24% at constant exchange rates with international sales up 128% and recurring revenue up 17%. In the United States we are selling at higher prices and lower discounts t...

Mauna Kea Technologies Announces 2026 Half-Year Results

PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today reports its consolidated results for the first half of 2026, as approved by the Board of Directors on September 28, 2026. The half-year financial report will be available on the Company's website. Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, commented: "T...

Mauna Kea Technologies : Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

PARIS--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Paris:ALMKT): Listing: Euronext Growth Paris ISIN code: FR0010609263, Ticker: ALMKT Website: www.maunakeatech.com Date Number of shares comprising the capital in circulation Total number of voting rights Gross Total (1) Net Total (2) September 30, 2026 199,066,710 200,153,761 200,153,761 (1) The gross number of voting rights (or "theoretical" voting rights) serves as the basis for calculating the thresholds. In accordance with Art...
Back to Newsroom